2020’s

• May

  MoU signed with Chonnam National University Hospital

  Apr

  Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96

2019’s

• Aug

  Completed Series B funding

  May

  Novartis drug development team(VP level) visits NEXEL HQ

  Mar

  Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products

2018’s

• Jun

  Innobiz Certification

  May

  Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan

  Mar

  ISO9001 certification

2017’s

• Dec

  Completed Series A funding
  

  Sep

  Invited to Novo Nordisk global collaboration business (with KOTRA)

  Aug

  MoU signed with T&R Biofab for the development of bioprinting technology using stem-cell derived cells

  May

  Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products

  Jan

  Domestic launch of cell products

2016’s

• Dec

  Tech. transfer of 6 patents from Korea University Industry-Academic Cooperation Foundation

  Nov

  License-in of cardiomyocyte differentiation technology from KIT

  Sep

  MoU signed for the development of toxicology platfoms using stem-cell derived cells with Korea Institute of Toxicology (KIT)

  Mar

  Corporate affiliated research institute certified
  

  Feb

  Venture company certified

2015’s

• May

  Name changed to NEXEL Co., Ltd.

2014’s

• Nov

  Picked as family company to Korea University Life Sciences College

  Sep

  MoU signed with IMPLAD China

2013’s

• Mar

  MoU signed with Korea University

2012’s

• Sep

  Founding of NEXCELL Bio